WO1995000665A1 - Thermodynamics, design, and use of nucleic acid sequences - Google Patents
Thermodynamics, design, and use of nucleic acid sequences Download PDFInfo
- Publication number
- WO1995000665A1 WO1995000665A1 PCT/US1994/006799 US9406799W WO9500665A1 WO 1995000665 A1 WO1995000665 A1 WO 1995000665A1 US 9406799 W US9406799 W US 9406799W WO 9500665 A1 WO9500665 A1 WO 9500665A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- value
- sequence
- duplex
- dna
- Prior art date
Links
- 150000007523 nucleic acids Chemical group 0.000 title claims abstract description 276
- 238000013461 design Methods 0.000 title description 6
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 234
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 234
- 238000000034 method Methods 0.000 claims abstract description 141
- 230000000295 complement effect Effects 0.000 claims abstract description 49
- 239000003446 ligand Substances 0.000 claims description 263
- 230000027455 binding Effects 0.000 claims description 233
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 112
- 238000012360 testing method Methods 0.000 claims description 108
- 230000003321 amplification Effects 0.000 claims description 76
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 76
- 238000009396 hybridization Methods 0.000 claims description 19
- 230000035772 mutation Effects 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 12
- 230000002596 correlated effect Effects 0.000 claims description 9
- 239000011541 reaction mixture Substances 0.000 claims description 9
- 108020004414 DNA Proteins 0.000 description 285
- 230000008018 melting Effects 0.000 description 175
- 238000002844 melting Methods 0.000 description 175
- 238000006243 chemical reaction Methods 0.000 description 97
- 238000003776 cleavage reaction Methods 0.000 description 83
- 230000003993 interaction Effects 0.000 description 82
- 230000007017 scission Effects 0.000 description 77
- 239000013615 primer Substances 0.000 description 74
- 102000004190 Enzymes Human genes 0.000 description 62
- 108090000790 Enzymes Proteins 0.000 description 62
- 238000002474 experimental method Methods 0.000 description 56
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 54
- 230000009257 reactivity Effects 0.000 description 49
- 230000001419 dependent effect Effects 0.000 description 48
- 230000000694 effects Effects 0.000 description 44
- 239000002131 composite material Substances 0.000 description 42
- 238000004458 analytical method Methods 0.000 description 37
- 230000007704 transition Effects 0.000 description 36
- 239000012634 fragment Substances 0.000 description 35
- 239000000758 substrate Substances 0.000 description 34
- 108010092160 Dactinomycin Proteins 0.000 description 27
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 27
- 229960000640 dactinomycin Drugs 0.000 description 27
- 108091008146 restriction endonucleases Proteins 0.000 description 26
- 239000000523 sample Substances 0.000 description 26
- 230000004568 DNA-binding Effects 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 239000003795 chemical substances by application Substances 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- 229940079593 drug Drugs 0.000 description 18
- 238000003541 multi-stage reaction Methods 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 17
- 125000003729 nucleotide group Chemical group 0.000 description 16
- 230000003287 optical effect Effects 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 15
- 239000002773 nucleotide Substances 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- -1 e.g. Proteins 0.000 description 14
- 238000013459 approach Methods 0.000 description 13
- 208000035475 disorder Diseases 0.000 description 13
- 229910052739 hydrogen Inorganic materials 0.000 description 13
- 239000001257 hydrogen Substances 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 12
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 12
- 239000011230 binding agent Substances 0.000 description 12
- 238000004364 calculation method Methods 0.000 description 12
- 239000000556 agonist Substances 0.000 description 11
- 239000005557 antagonist Substances 0.000 description 11
- 230000000875 corresponding effect Effects 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 11
- 230000000977 initiatory effect Effects 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 108010006785 Taq Polymerase Proteins 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 230000036961 partial effect Effects 0.000 description 9
- 230000004913 activation Effects 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- XCWHINLKQMCRON-VHXPCKQRSA-N gilvocarcin V Natural products COc1cc(C=C)cc2C(=O)Oc3c(cc(OC)c4c(O)ccc([C@H]5O[C@@H]([C@H](C)O)[C@H](O)[C@H]5O)c34)c12 XCWHINLKQMCRON-VHXPCKQRSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- XCWHINLKQMCRON-UCDARZNSSA-N 4-[(2R,3R,4R,5S)-3,4-dihydroxy-5-[(1R)-1-hydroxyethyl]oxolan-2-yl]-8-ethenyl-1-hydroxy-10,12-dimethoxynaphtho[1,2-c]isochromen-6-one Chemical compound COC1=CC(C=C)=CC(C(OC2=C34)=O)=C1C2=CC(OC)=C3C(O)=CC=C4[C@H]1O[C@@H]([C@@H](C)O)[C@H](O)[C@H]1O XCWHINLKQMCRON-UCDARZNSSA-N 0.000 description 7
- 241000283891 Kobus Species 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 108091093088 Amplicon Proteins 0.000 description 5
- 108020001019 DNA Primers Proteins 0.000 description 5
- 239000003155 DNA primer Substances 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 238000012937 correction Methods 0.000 description 5
- 238000000113 differential scanning calorimetry Methods 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 230000007023 DNA restriction-modification system Effects 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 238000010504 bond cleavage reaction Methods 0.000 description 4
- 230000006911 nucleation Effects 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 108700020942 nucleic acid binding protein Proteins 0.000 description 4
- 102000044158 nucleic acid binding protein Human genes 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 238000004445 quantitative analysis Methods 0.000 description 4
- 230000008707 rearrangement Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000009830 intercalation Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000012772 sequence design Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 238000010256 biochemical assay Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 230000000368 destabilizing effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000002848 electrochemical method Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000008570 general process Effects 0.000 description 2
- 229930184938 gilvocarcin Natural products 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 description 2
- 230000002687 intercalation Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000037230 mobility Effects 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 231100000707 mutagenic chemical Toxicity 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000007502 viral entry Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- NOIRDLRUNWIUMX-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;6-amino-1h-pyrimidin-2-one Chemical compound NC=1C=CNC(=O)N=1.O=C1NC(N)=NC2=C1NC=N2 NOIRDLRUNWIUMX-UHFFFAOYSA-N 0.000 description 1
- 229930091051 Arenine Natural products 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108020005124 DNA Adducts Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 230000005366 Ising model Effects 0.000 description 1
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 238000012565 NMR experiment Methods 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 101710136739 Teichoic acid poly(glycerol phosphate) polymerase Proteins 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000008711 chromosomal rearrangement Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- SPTYHKZRPFATHJ-HYZXJONISA-N dT6 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 SPTYHKZRPFATHJ-HYZXJONISA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000011880 melting curve analysis Methods 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000012569 microbial contaminant Substances 0.000 description 1
- 238000012821 model calculation Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000011330 nucleic acid test Methods 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 108010083127 phage repressor proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- QVLTXCYWHPZMCA-UHFFFAOYSA-N po4-po4 Chemical compound OP(O)(O)=O.OP(O)(O)=O QVLTXCYWHPZMCA-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
Definitions
- This invention relates to the formation and dissolution of double stranded nucleic acid molecules and to the interactions between double and single stranded nucleic acid molecules and nucleic acid-binding ligands.
- DNA sequence design and construction including, e.g., methods for determining and preparing DNA sequences with selected reaction attributes, such as binding affinities for their respective ligands; and the use of such sequences in diagnostic or analytical procedures to detect target DNA, e.g., viral DNA.
- the invention features, a method of providing the sequence of a single stranded nucleic acid molecule, which, when hybridized to a complementary single stranded molecule, results in a double stranded (duplex) structure having a preselected value for a free energy parameter, e.g., a preselected T m or a preselected affinity for a nucleic acid binding ligand.
- a free energy parameter e.g., a preselected T m or a preselected affinity for a nucleic acid binding ligand.
- the method includes:
- the value of the free energy-parameter formed by the hybridization of a test single stranded nucleic acid molecule to a complementary sequence (formed in step (1)) does not exhibit a preselected relationship with the reference value and a subsequent test single strand nucleic acid molecule is provided by permuting the test single strand nucleic acid molecule.
- steps (1), (2), and (3) are performed to provide a first single stranded nucleic acid sequence which can form a duplex having a preselected value for a free energy parameter, and the cycle of steps (1), (2), and (3), are repeated using the first single stranded nucleic acid as a starting point to provide a second single stranded molecule (which is a permutation of the first) which when hybridized to a complimentary single stranded nucleic acid results in a duplex having a preselected value for a free-energy parameter.
- the second single strand nucleic acid molecule can have a value for a free-energy parameter which is greater than, or less than, the value of the parameter for the first single strand nucleic acid molecule.
- the method provides nucleic acid molecules with defined values for a free energy parameter. Since the value for the parameter is related to a number of important properties, e.g., ligand binding, melting temperature, affinity for a target sequence, resistance of a duplex to perturbation, the method allows for the provision of nucleic acid molecules tailored to specific applications. E.g., as is discussed herein, it allows the production of nucleic acid molecules with a defined affinity for a ligand which binds to the DNA and regulates, e.g., promotes, the expression of a protein encoded by the nucleic acid.
- the invention features a method for providing a flanking nucleic acid sequence which is useful as a flanking sequence to a site, e.g., a binding site for a ligand and, e.g., which modulates a free energy parameter of the site, e.g., the T m , of a site or the affinity of a binding site for the ligand.
- the flanking nucleic acid sequence is such that when incorporated into a single stranded nucleic acid encoding the site (e.g., as a sequence which flanks a binding site), and the resulting single stranded molecule hybridized to a complementary sequence, a duplex having a preselected value for a free energy parameter is formed.
- a duplex having a preselected T m is formed, the duplex having a site which has a T m of a preselected value, a ligand binding constant of a preselected value, or a preselected value for the composite rate of reaction of the ligand.
- the method includes:
- the value of the free energy-parameter formed by the hybridization of a test single stranded nucleic acid molecule to a complementary sequence (formed in step (1)) does not exhibit a preselected relationship with the reference value and a subsequent test single strand nucleic acid molecule is provided by permuting the test single strand nucleic acid molecule.
- steps (1), (2), and (3) are performed to provide a first single stranded nucleic acid sequence which can form a duplex having a preselected value for a free energy parameter, and the cycle of steps (1), (2), and (3), are repeated using the first single stranded nucleic acid as a starting point to provide a second single stranded molecule (which is a permutation of the first) which when hybridized to a complimentary single stranded nucleic acid results in a duplex having a preselected value for a free-energy parameter.
- the second single strand nucleic acid molecule can have a value for a free-energy parameter which is greater than, or less than, the value of the parameter for the first single strand nucleic acid molecule.
- the method allows for the alteration of a property of a site, e.g.,. ligand binding, melting temperature, affinity for a target sequence, resistance or suseptability of a duplex to perturbation, without affecting the sequence of the site itself.
- a property of a site e.g.,. ligand binding, melting temperature, affinity for a target sequence, resistance or suseptability of a duplex to perturbation
- the binding affinity of a ligand having an extremely specific binding site sequence requirement can be modulated without changing the sequence of the site by providing the appropriate flanking sequence.
- the invention features a method of optimizing the binding of a ligand to a nucleic acid, by providing an optimized binding site.
- the method includes:
- test nucleic acid sequence which includes or flanks the binding site
- steps (1), (2), and (3) are performed to provide a first sequence having a preselected value for a free energy parameter, and the cycle of steps (1), (2), and (3), repeated using the first sequence as a starting point to provide a second single stranded molecule (which is a permutation of the first) a duplex having a preselected value for a free-energy parameter.
- the second sequence can have a value for a free-energy parameter which is greater than, or less than, the value of the parameter for the first sequence.
- the permuted sequence is subjected to one or more subsequent cycles of steps (2) and (3) above, to further optimize the site.
- the permutations in subsequent cycles can be at the same base pair as in the first cycle or at different base pairs. Subsequent cycles can be repeated, e.g., until no fiirther optimization is gained or until a predetermined number of cycles has been performed.
- the site controls, e.g., at the transcriptional level, the expression of an RNA or a peptide;
- the binding site is a binding site for a nucleic acid binding protein, e.g., a sequence-specific nucleic acid binding protein, or a protein which binds in a sequence non-specific manner;
- the site is in or near an element which regulates transcription (wherein near means sufficiently close for binding to affect control of a seqeunce under the control of the element);
- the site is near or in an enhancer;
- the site is in or near a promoter;
- the site is the site of binding of a ligand which affects recombination, viral entry into a nucleic acid, or replication of a nucleic acid.
- the invention allows for the construction of useful binding sites, e.g., promoter or other control sequences sites which are engineered to express a product at a defined level, or sites which are engineered to support amplification at a defined level.
- useful binding sites e.g., promoter or other control sequences sites which are engineered to express a product at a defined level, or sites which are engineered to support amplification at a defined level.
- the invention features, a method for providing a set of nucleic acid primers.
- the set of primers includes: a first single stranded primer which when hybridized to a complementary single stranded molecule, results in a first double stranded (duplex) structure having a first value for a free energy parameter, e.g., a preselected T m or a preselected affinity for a nucleic acid binding ligand, e.g., a DNA polymerase, e.g., Tag polymerase, or which supports the amplification of a product from a region of the first duplex at a first rate of amplification; and a second single stranded primer which when hybridized to a complementary single stranded molecule, results in a second double stranded (duplex) structure having a second value for a free energy parameter, e.g., a preselected T m or a preselected affinity for a nucleic acid binding ligand
- the value of the free energy-parameter formed by the hybridization of a test single stranded nucleic acid molecule to a complementary sequence (formed in step (1)) does not exhibit a preselected relationship with the reference value and a subsequent test single strand nucleic acid molecule is provided by permuting the test single strand nucleic acid molecule.
- steps (1), (2), and (3) are performed to provide a first single stranded nucleic acid sequence which can form a duplex having a preselected value for a free energy parameter, and the cycle of steps (1), (2), and (3), are repeated using the first single stranded nucleic acid as a starting point to provide a second single stranded molecule (which is a permutation of the first) which when hybridized to a complementary single stranded nucleic acid results in a duplex having a preselected value for a free-energy parameter.
- the second single strand nucleic acid molecule can have a value for a free-energy parameter which is greater than, or less than, the value of the parameter for the first single strand nucleic acid molecule.
- the method further includes providing a second primer by:
- Matched primers can be used e.g., to amplify two or more separate target sequences at approximately the same rate, providing for multiplexed amplification reactions, e.g., multiplexed PCR reactions.
- multiplexed amplification reactions e.g., multiplexed PCR reactions.
- a relatively small difference in amplification rate at a first site and the amplification rate at a second site will, after a relatively small number of cycles of amplification, result in a relatively great preponderance of the products generated from the site with the higher amplification rate.
- the more highly amplified site produces a signal which "swamps" the signal from the less highly amplified site.
- the signal from two (or more) amplified sites can be more easily detected in a single reaction mixture.
- the method allows relatively easy, convenient, and reliable detection of more than one target sequence in a sample. E.g., a single sample can be tested, simultaneously, for the presence of two or more microbial
- Matched primers of the invention can be used to test a single sample of a biological fluid, e.g., blood, serum, plasma, or urine, for the presence of multiple target sequences in a single reaction, e.g., to detect the presence of a plurality of disease causing organisms in a single reaction.
- the primers are useful for detecting organisms which contribute to septecemia, e.g., a bacterium, e.g., a gram negative bacterium, an anerobic infectious agent, a streptococcal agent, a staphlyloccocal agent, a pneumococcal agent, E. coli, or psuedomonas.
- Tm for two oligonucleotides primers used in a reaction is all that is required to specify the difference in binding constant of the polymerase for the two sites and the rates of amplicon formation. This is of particular value in multiplex PCR reactions. As long as the Tm of two primers is held at the essentially the same value (by appropriate primer design) the amplicons will be produced at essentially the same rate. This is because the rate of production is dependent on binding and enzymatic extension steps of the polymerase during the cycling reaction.
- the invention also provides a method of determining if an amplified signal, e.g., the amplified signal in a PCR reaction, is a false positive, by comparing the rate of amplification for the signal with the rates for one or more signals generated by primers with known or matched rates. A rate of amplification which differs from that of the added primers is indicative that the signal is a false positive.
- the invention also includes primers or other sequences or molecules made by the methods of the invention.
- the invention features, a set of primers, or a reaction mixture, including: a first single stranded primer which when hybridized to a complementary single stranded molecule, results in a first double stranded (duplex) structure having a first value for a free energy parameter, e.g., a preselected T m or a preselected affinity for a nucleic acid binding ligand, e.g., a DNA polymerase, e.g., Taq polymerase, or which supports the amplification of a product from a region of the first duplex at a first rate of amplification; and a second single stranded primer which when hybridized to a complementary single stranded molecule, results in a second double stranded (duplex) structure having a second value for a free energy parameter, e.g., a preselected T m or a preselected affinity for a nucleic acid binding ligand, e.g.,
- Methods of the invention use thermochemical data to evaluate duplex stability of nucleic acid sequences including or flanking a binding site or a site of reaction.
- a direct correlation derived therefrom between duplex stability and either relative binding constant or composite reaction rate provides a rule for determining at least one DNA sequence that can be employed as a flanking sequence to a DNA binding site for the ligand with resulting relative increase, decrease, or equality in binding constant of the ligand for its binding site or in composite reaction rate for reaction between the ligand and the DNA sequence.
- These methods allow adjustment of reaction or binding parameters of a DNA sequence towards a ligand, including but not limited to a restriction enzyme, ligase, or polymerase.
- Methods of the invention provide for the development of highly accurate protocols using DNA amplification strategies (such as those based on the polymerase chain reaction) for the diagnosis of disease states caused by viral DNA and difficult to determine with high certainty by any known method in the art, in part because of significant analytical difficulties in reliably detecting the identity of the related DNA sequences at ultralow levels.
- An important example of a DNA disease virus is human immunodeficiency virus, wherein false positives can have serious psychological and social consequences.
- the invention features a method of predicting the relative susceptibility of a site on a nucleic acid duplex to perturbation. The method includes: determining the value of a free energy-parameter of a duplex which includes or flanks the site, the value for the free energy parameter being predictive of the susceptibility of the site to perturbation.
- the value for a free energy parameter is determined by, beginning at a first base pair of the duplex, determining a value for the free-energy parameter of n base pairs in a window (a window is a number of bases, preferably adjacent bases), where n is any integer between 1 and 1,000, inclusive, (preferably n is less than 10, 20, 30, 40, 50, 100, 200, 300, 400, 500, or 1 ,000) moving the window to another base pair, and determining a value for the free energy parameter of the next window, and repeating the process for some or all of the remaining base pairs of the duplex, preferably, the windows are determined in the linear order in which they appear on the duplex; the free energy ⁇ Gj)° of duplex melting for the duplex which includes or flanks the site is determined, e.g., by summing free-energy values for hydrogen-bonding and stacking interactions for the nucleotide bases constituting the sequence; free-energy values are predetermined by semi- empirical thermochemical methods; the free energy of melting for n base pairs in
- the method further includes, providing a nucleic acid sample (which includes the site) from a subject, and determining (e.g., by determining the value of a free energy parameter for the duplex) if there is a mutation (e.g., a mutation which alters the value of a free energy parameter at the site) in the site, a mutation at the site being indicative of risk of a disorder, e.g., a neoplastic disorder.
- the method also allows identification of mutations which are likely to alter the reactivity of the duplex (e.g., mutations which would render the duplex more likely to bind a ligand, e.g., a ligand which regulates the expression of a protein).
- the invention allows the discovery of sites which are susceptible to perturbation, e.g., to mutation.
- This method can be used to identify sites which are susceptible to mutation, and can thus identify sites in a gene which may be useful in determining if an individual is at risk for a disorder related to a lesion in the gene.
- the invention features a method of constructing a map of the relative susceptibility to perturbation, e.g., mutation, of a plurality of sites in a region of a nucleic acid duplex.
- the method includes: ( 1 ) determining the value of a free energy-parameter of a first site in the region, the free energy parameter being correlated to susceptibility to perturbation; and
- a map of the relative susceptibilities to perturbation sensitive regions is useful for detecting gene coding regions (which are relatively stable regions), detecting gene control regions (which tend to be more stable than even coding regions), or to detect sites of preferential reactivity.
- Methods described herein allow direct and explicit determination of the site specific reactivity of a ligand, e.g., an enzyme, which interacts with or effects changes upon a nucleic acid, e.g, a DNA.
- a ligand e.g., an enzyme
- Methods of the invention rely, in part, on the refinement of thermodynamic values for duplex stability. It is shown herein that if one can explicitly determine the reactivity of different DNA sequences with the same ligand, then differences observed are due solely to the difference in DNA sequence.
- E any enzyme
- D is a given DNA sequence
- ED is the complex between the enzyme and DNA
- P is the product(s) produced the action of E on D.
- the overall rate of this reaction, k c can be expressed as
- k c the composite second order rate constant for the reaction (two reactants and one product)
- ⁇ l forward rate constant for the first step
- k_ ⁇ reverse rate constant for the first step
- k 2 the rate constant for catalysis
- K ⁇ kj/k_ ⁇ the equilibrium constant for forming the bound complex (e.g.,
- K a constant that relates the composite activation free energy to the free energy of melting the duplex.
- Figs. 1(a) and 1(b) are graphs of free energy profiles calculated for 30 base pair windows of the 1635 bp Hinfl restriction fragment sequence from pBR322.
- Fig. 1(a) free-energy profiles calculated using the sets of n-n interactions in columns A, B and C of
- Table 1 The uppermost curve was calculated from the values in column B. The next upper curve was calculated from the values in column C. The bottom curve is the energy profile calculated using the values in column A. Beginning at the first bp of the sequence, the free-energy of 30 bps in a window was calculated and plotted as a point. The window was then moved one bp and the energy of the next 30 bp window was calculated. Repeating the process to the end of the sequence results in the plots in Fig. 1(a).
- Fig. 1(b) shows the difference curves of the plots in Fig. 1(a).
- Three plots of the normalized differences calculated as described in the text are shown in arbitrary units.
- the top curve is the difference profile for the differences between the uppermost curve and lowest curve in Fig. 1(a).
- the middle curve is the difference between the middle and lowest energy profiles in Fig. 1(a).
- the lowest difference plot corresponds to the difference between the two upper curves in Fig. 1(a).
- Figs. 2(a) and 2(b) are graphs of free energy profiles calculated for 120 base pair windows of the 1635 bp Hinfl restriction fragment sequence from pBR322. In Fig. 2(a), exactly as in Fig 1(a) except the energy profiles were calculated using a 120 bp window.
- Fig. 2(b) exactly as in Fig 1(b) except these energy difference profiles were calculated from the energy profiles in Fig. 2(a) determined at a window of 120 bps.
- Fig. 3 is a list of the sequences of the seven duplexes prepared and examined in the studies described in the text are shown. Abbreviations for the molecules are given at the right and used for reference throughout the text ((AA) (SEQ ID NO: 5); (AT) 2 (SEQ ID NO: 4); (AA) (SEQ ID NO: 3); (AT) 3 (SEQ ID NO: 2); (AA)(AT) 2 (SEQ ID NO: 6); (AA) (SEQ ID NO: 8); and (AT) 4 (SEQ ID NO: 7)).
- Figs. 5 (AT) 2 (SEQ ID NO: 4);
- AA SEQ ID NO: 3
- AT 3 (SEQ ID NO: 2
- FIG. 4(a) and 4(b) are graphs of Van't Hoff plots obtained from melting curves of the seven DNA molecules. Transition temperatures were obtained from melting curves of the molecules in Fig 3 conducted in 115 mM Na + as a function of total strand concentration, C ⁇ ; and plotted as shown.
- the van't Hoff plots for the AT series, (AT) 2 (SEQ ID NO: 3), (AT)3 (SEQ ID NO: 1), (AT)4 (SEQ ID NO: 6) are shown in Fig. 4(a).
- Fig. 5 is a plot of the helix initiation parameter versus duplex length.
- the natural log of the helix initiation factor, ⁇ is plotted versus the number of bps in the duplex.
- Three sets of data and linear fits to them are shown.
- the upper-most set (triangles, dashed line) was determined from experiments in 75 mM Na + , and was constructed from the average values given in column B of Table 5.
- the middle set (circles, solid line) was determined from experiments in 115 mM Na + , and was constructed from the average values in column C of Table 5.
- the lower-most curve (squares, broken line) was determined from experiments in 1.0 M Na + , and was constructed from the average values in column A of Table 5.
- the error bars indicate deviations from the averages for DNAs of different lengths. In the cases of the upper-most and lower-most plots the larger deviations may be due to differences in solvent environments for the calculated free-energies and experiments where the free-energies of the DNAs were actually determined. These plots show the free energy of helix initiation, ⁇ Gint, is essentially constant for these DNAs ranging from 12 to 20 bps in length.
- Figs. 6(a) and 6(b) are representations of DNAse I footprints of Actinomycin D.
- Results of the DNAse I footprinting experiments of (AT)3 (SEQ ID NO: 1) (a) and (AA)3 (SEQ ID NO: 2) (b) in Fig. 3 bound by increasing amounts of Actinomycin D at the central AGCT site of these sequences are shown.
- Base pair positions are shown on the horizontal axis.
- Intensities determined from bands after electrophoretic analysis of partial cleavage products of DNAse I are indicated on the vertical axis.
- Drug: duplex stoichiometry increases going into the Figure. Band intensities corresponding to cleavage enhancements away from the drug binding site are clearly seen.
- Figs. 7 (a)-(d) are depictions of proton chemical shift changes in a sixteen base pair duplex DNA bound by Actinomycin D.
- the 16 bp sequence AA(AT) 2 (SEQ ID NO: 5) is shown at the top.
- the quinoid (Q) and benzenoid (B) ring positions of actinomycin D are indicated.
- the asterisks indicate sites of DNAse I cleavage enhancements induced by bound drug determined in independent experiments. Changes in chemical shift, ⁇ (ppm) of the H3' Fig. 7(a), H4' Fig. 7(b), H8/H6 Fig. 7(c) and HI' Fig.
- the fraction of first strand cleaved product by Alu I as a function of time, f c (t), is plotted versus time for each of the DNAs shown in Fig 3.
- the data were collected at least two times on different labeled DNA samples under identical conditions.
- a summary of the results for all molecules is shown.
- Rate plots for the (AT) series molecules, (AT) 2 (SEQ ID NO: 3), (ATt ⁇ (SEQ ID NO: 1), and (AT)4 (SEQ ID NO: 6) are shown on the left.
- Rate plots for the (.AA) series molecules, (AA) 2 (SEQ ID NO: 4), (AA)3 (SEQ ID NO: 2), and (AA)4 (SEQ ID NO: 7) are shown on the right.
- the rate plot for the hybrid molecule, AA(AT) 2 (SEQ ID NO: 5) is shown in the middle. Slopes of these plots decrease with increasing length and are greater for molecules from the (AT) series than for molecules from the (AA) series of the same size. From these slopes the observed first order rate constants for first strand cleavage were obtained. Results are summarized in Table 6.
- Fig. 9 is a plot of the observed rate constants for first strand cleavage of the seven DNA molecules versus duplex length.
- the observed rate constants for first strand cleavage by Alu I . kobs . of the seven DNA molecules in Fig 3, determined from the data in Fig 8 and summarized in Table 6, are plotted versus duplex length. A clear increase in k 0 bs is seen with decreasing duplex length.
- the 16 bp molecule with neither purely (AT) or purely (AA) flanking sequences, AA(AT) 2 (SEQ ID NO: 5), has a cleavage rate intermediate between the 16 bp molecules with (AT) and (AA) flanking sequences.
- Fig. 10 is a plot of the observed rate constants for first strand cleavage of the seven DNA molecules versus their free-energies of melting.
- the quantity -RTlnk 0 bs determined from Table 6 is plotted versus the free-energy of duplex melting, - ⁇ GD, for the seven DNAs in Fig 3.
- Experimentally determined values are summarized is Table 4. This plot reveals that melting free-energy is linearly proportional to -RTlnk 0 bs . and this proportionality depends quite dramatically on duplex length. Lines sketched through the data extrapolate to a single intersection point (circled) suggesting the observed differences in cleavage behavior are due to free-energys of only the flanking sequences. In fact, the intersection point (dashed line) corresponds precisely to the calculated melting free-energy (-5.2 kcal/mol) of the central four bp sequence AGCT.
- Fig. 11 is a plot of the reactivity of two duplex DNA's with the anti-tumor agent gilvocarcin V.
- the percent of UV adduct formation (% modified) for the 16 bp DNAs (AA)3 (SEQ ID NO: 2) (filled circles) and (AT)3 (SEQ ID NO: 1) (open triangles) versus irradiation time by broad band ultraviolet light ( ⁇ 254 nm, supplied by a handheld lamp with output of approximately 2200 watts/cm ⁇ ).
- ⁇ 254 nm, supplied by a handheld lamp with output of approximately 2200 watts/cm ⁇ .
- modification occurs at a greater rate for (AT)3 (SEQ ID NO: 1) than for (AA)3 (SEQ ID NO: 2).
- the observed difference in reactivities for these similar DNA sequences with gilvocarcin is analogous to similar observations made for reactivities of these DNAs with other agents as summarized in Table 7.
- the invention features, a method of providing the sequence of a single stranded nucleic acid molecule, which, when hybridized to a complementary single stranded molecule, results in a double stranded (duplex) structure having a preselected value for a free energy parameter, e.g., a preselected T m or a preselected affinity for a nucleic acid binding ligand.
- a free energy parameter e.g., a preselected T m or a preselected affinity for a nucleic acid binding ligand.
- the method includes:
- the value of the free energy-parameter formed by the hybridization of a test single stranded nucleic acid molecule to a complementary sequence (formed in step (1)) does not exhibit a preselected relationship with the reference value and a subsequent test single strand nucleic acid molecule is provided by permuting the test single strand nucleic acid molecule.
- steps (1), (2), and (3) are performed to provide a first single stranded nucleic acid sequence which can form a duplex having a preselected value for a free energy parameter, and the cycle of steps (1), (2), and (3), are repeated using the first single stranded nucleic acid as a starting point to provide a second single stranded molecule (which is a permutation of the first) which when hybridized to a complimentary single stranded nucleic acid results in a duplex having a preselected value for a free-energy parameter.
- the second single strand nucleic acid molecule can have a value for a free-energy parameter which is greater than, or less than, the value of the parameter for the first single strand nucleic acid molecule.
- the value of the free-energy parameter can be determined, e.g., empirically, semi- empirically, or by calculation, e.g., by a method described herein, or by any method known to those in the art.
- the value for a free energy parameter is determined by, beginning at a first base pair of the duplex, determining a value for the free-energy parameter of n base pairs in a window, where n is any integer between 1 and 1,000, inclusive, (preferably n is less than 10, 20, 30, 40, 50, 100, 200, 300, 400, 500, or 1,000) moving the window to another base pair, and determining a value for the free energy parameter of that window, and repeating the process on some or all of the base pairs of the duplex, preferably, the windows are determined in the linear order in which they appear on the duplex; the free energy ⁇ GD° of duplex melting for the duplex formed by a single stranded sequence is determined, e.g., by summing free-energy values for hydrogen-bonding and stacking interactions for the nucleotide bases constituting the sequence; free-energy values are predetermined by semi-empirical thermochemical methods; the free energy of melting for a duplex is determined by an equation, e.g.,
- ⁇ Gtotal ⁇ i Gy+i + ⁇ G S ym + ⁇ Gint
- ⁇ Gj i+ ⁇ is the free-energy of the nearest-neighbor base pair doublet formed by base pairs i and i+1 that includes both the hydrogen bonding and stacking free-energies included in the doublet.
- ⁇ G S y m is a symmetry correction term required if the two single strands have exactly the same sequence.
- ⁇ Gint is the free energy of helix initiation.
- the method includes: relating the reactivity of a duplex to another free energy parameter, e.g.,T m , by the proprtionality constant or function K , wherein K can be determined by determining a free energy parameter, e.g.
- free energies ⁇ G ⁇ j° of duplex melting, for the duplex formed by each test single stranded nucleic acid molecule e.g., by summing free-energy values for hydrogen-bonding and stacking interactions for the nucleotide bases constituting each potential single strand sequence, wherein such free-energy values are predetermined by semi-empirical thermochemical methods and determining relative composite reaction rates for the selected potential single stranded sequences by means of an equation, e.g., by the following equation,
- k and k ⁇ are relative composite rate constants of a reaction for any two DNA sequences I and II, respectively, i and K.H are relative binding constants for the ligand to any two DNA sequences I and II, respectively, R is the universal gas constant, T is absolute temperature, K is a proportionality constant or function, wherein K is predetermined in accord with the above-recited equations for the ligand and for set sequence length by calculating free energies of melting ⁇ Gj ° for at least two preselected DNA flanking sequences if K is a proportionality constant, or at least three if a function, determined in accord with the summing step; a value for K is determined by measuring relative or actual composite rates of reaction or binding constants for synthetic or native DNA sequences containing the preselected DNA flanking sequences and relating the measured relative composite rates of reaction or binding constants to their respective differences in free energy of melting ⁇ Gj)° as determined in accord with above-recited equations; and choosing a test single strand nucleic acid providing
- Every ligand has a K.
- K relates the reactivity of a nucleic acid to another free energy parameter, e.g.,T m .
- K can be used to relate the reactivity of a nucleic acid to another free energy parameter when the ligand binder is a duplex or a single strand binder, or when the nucleic acid is a single strand or a duplex.
- the invention features a method for providing a flanking nucleic acid sequence which is useful as a flanking sequence to a site, e.g., a binding site for a ligand and, e.g., which modulates a free energy parameter of the site, e.g., the T m of a site or the affinity of a binding site for the ligand.
- the flanking nucleic acid sequence is such that when incorporated into a single stranded nucleic acid encoding the site (e.g., as a sequence which flanks a binding site), and the resulting single stranded molecule hybridized to a complementary sequence, a duplex having a preselected value for a free energy parameter is formed.
- a duplex having a preselected T m is formed, the duplex having a site which has a T m of a preselected value, a ligand binding constant of a preselected value, or a preselected value for the composite rate of reaction of the ligand.
- the method includes: (1 ) determining the value of a free energy-parameter of a duplex formed by the hybridization of a test single stranded nucleic acid molecule (which, e.g., includes a site and a flanking sequence) to a complementary sequence;
- the value of the free energy-parameter formed by the hybridization of a test single stranded nucleic acid molecule to a complementary sequence (formed in step (1)) does not exhibit a preselected relationship with the reference value and a subsequent test single strand nucleic acid molecule is provided by permuting the test single strand nucleic acid molecule.
- steps (1), (2), and (3) are performed to provide a first single stranded nucleic acid sequence which can form a duplex having a preselected value for a free energy parameter, and the cycle of steps (1), (2), and (3), are repeated using the first single stranded nucleic acid as a starting point to provide a second single stranded molecule (which is a permutation of the first) which when hybridized to a complimentary single stranded nucleic acid results in a duplex having a preselected value for a free-energy parameter.
- the second single strand nucleic acid molecule can have a value for a free-energy parameter which is greater than, or less than, the value of the parameter for the first single strand nucleic acid molecule.
- the binding of a ligand to each test sequence or molecule is determined, either empirically, or from calculations from known ligand properties.
- the preselected value for the parameter can be can be increased relative to, decreased relative to, or approximately equal to, a reference value conferred on a duplex by a reference single stranded molecule, e.g., by a reference sequence.
- the site is: a base pair; a plurality of base pairs, e.g., n base pairs wherein p is an integer between 1 and 1,000; the site is less than 10, 20, 30. 40, 50, 100, 200, 400, 500, or 1,000 base pairs in length.
- the value of the free-energy parameter can be determined, e.g., empirically, semi- empirically, or by calculation, e.g., by a method described herein, or by any method known to those in the art.
- the method includes determining the free energy of melting of a duplex formed by the hybridization of a test single stranded nucleic acid molecule to a complementary sequence, and comparing that free energy with a reference value for free energy, e.g., the free energy of melting, ⁇ Grj°, of a reference sequence.
- the determined free energy of melting is, greater than the reference value (e.g., in the case where an increase (relative to the affinity of the ligand for a duplex with the reference value for free energy) in ligand affinity or composite rate is desired), lower than the reference value (e.g., in the case where a decrease (relative to the affinity of the ligand for a duplex with the reference value for free energy) in ligand affinity or composite rate is desired), or approximately equal to the reference value (e.g., in the case where a ligand affinity or composite rate which is approximately equal to the affinity of the ligand for a duplex with the reference value for free energy is desired), using all or part of the test sequence as all or part of the flanking sequence.
- the value for a free energy parameter is determined by, beginning at a first base pair of the duplex, determining a value for the free-energy parameter of n base pairs in a window, where n is any integer between 1 and 1,000, inclusive, (preferably n is less than 10, 20, 30, 40, 50, 100, 200, 300, 400, 500, or 1,000) moving the window to another base pair, and determining a value for the free energy parameter of the next window, and repeating the process on some or all of the remaining base pairs of the duplex, preferably, the windows are determined in the linear order in which they appear on the duplex; the free energy ⁇ Gj) 0 of duplex melting for the duplex formed by a test single stranded nucleic acid molecule is determined, e.g., by summing free-energy values for hydrogen-bonding and stacking interactions for the nucleotide bases constituting the sequence; free-energy values are predetermined by semi-empirical thermochemical methods; the free energy of melting for a duplex is
- ⁇ Gtotal ⁇ i ⁇ Gy+i + ⁇ G sy m + ⁇ Gint •
- the method includes: relating the reactivity of a duplex to another free energy parameter, e.g.,T m , by the proportionality constant or function K , wherein K can be determined by determining a free energy parameter, e.g.
- free energies ⁇ G ⁇ J° of duplex melting, for the duplex formed by each test single stranded nucleic acid molecule e.g., by summing free-energy values for hydrogen-bonding and stacking interactions for the nucleotide bases constituting each potential single strand sequence, wherein such free-energy values are predetermined by semi-empirical thermochemical methods and determining relative composite reaction rates for the selected potential single stranded sequences by means of an equation, e.g., by the following equation,
- the calculated relative binding constants are determined by means of an equation, e.g., the equation,
- K is a proportionality constant or function, wherein K is predetermined in accord with the above-recited equations for the ligand and for set sequence length by calculating free energies of melting ⁇ Gj) 0 for at least two preselected DNA flanking sequences if K is a proportionality constant, or at least three if a function, determined in accord with the summing step; a value for K is determined by measuring relative or actual composite rates of reaction or binding constants for synthetic or native DNA sequences containing the preselected DNA flanking sequences and relating the measured relative composite rates
- Every ligand has a K.
- K relates the reactivity of a nucleic acid to another free energy parameter, e.g.,T m .
- K can be used to relate the reactivity of a nucleic acid to another free energy parameter when the ligand binder is a duplex or a single strand binder, or when the nucleic acid is a single strand or a duplex.
- the invention features a method of optimizing the binding of a ligand to a nucleic acid, by providing an optimized binding site.
- the method includes: (1) providing a test nucleic acid sequence which includes or flanks the binding site;
- steps (1), (2), and (3) are performed to provide a first sequence having a preselected value for a free energy parameter, and the cycle of steps (1), (2), and (3), repeated using the first sequence as a starting point to provide a second single stranded molecule (which is a permutation of the first) a duplex having a preselected value for a free-energy parameter.
- the second sequence can have a value for a free-energy parameter which is greater than, or less than, the value of the parameter for the first sequence.
- the permuted sequence is subjected to one or more subsequent cycles of steps (2) and (3) above, to further optimize the site.
- the permutations in subsequent cycles can be at the same base pair as in the first cycle or at different base pairs.
- Subsequent cycles can be repeated, e.g., until no further optimization is gained or until a predetermined number of cycles has been performed.
- the site controls, e.g., at the transcriptional level, the expression of an RNA or a peptide;
- the binding site is a binding site for a nucleic acid binding protein, e.g., a sequence-specific nucleic acid binding protein, or a protein which binds in a sequence non-specific manner;
- the site is in or near an element which regulates transcription (wherein near means sufficiently close for binding to affect control of a seqeunce under the control of the element);
- the site is near or in an enhancer;
- the site is in or near a promoter;
- the site is the site of binding of a ligand which affects recombination, viral entry into a nucleic acid, or replication of a nucleic acid.
- binding is optimized to increase or decrease the expression of an mRNA or a peptide under the control of the sequence; binding is optimized to coordinate the expression of an mRNA or peptide under control of the sequence with the expression of an mRNA or peptide not under transcriptional control of the sequence.
- the sequence is a eukaryotic sequence; the sequence exerts translational control over a prokaryotic or eukaryotic mRNA encoding sequence; the identity of the ligand is known; the ligand is unknown; the method further includes expressing an mRNA or peptide under the control of the sequence; the method further includes determining the binding site of the ligand, e.g., by mutational or footprint analysis.
- the site is: a base pair; a plurality of base pairs, e.g., p base pairs wherein n is p is an integer between 1 and 1,000, inclusive; the site is less than 10, 20, 30. 40, 50, 100, 200, 400, 500, or 1,000 base pairs in length.
- the value of the free-energy parameter can be determined, e.g., empirically, semi- empirically, or by calculation, e.g., by a method described herein, or by any method known to those in the art.
- the value for a free energy parameter is determined by, beginning at a first base pair of the duplex, determining a value for the free-energy parameter of n base pairs in a window, where n is any integer between 1 and 1,000, inclusive, (preferably n is less than 10, 20, 30, 40, 50, 100, 200, 300, 400, 500, or 1,000) moving the window to another base pair, and determining a value for the free energy parameter of the next window, and repeating the process for some or all of the remaining base pairs in the duplex, preferably, the windows are determined in the linear order in which they appear on the duplex; the free energy ⁇ G ⁇ j° of duplex melting for the duplex formed by a single stranded sequence is determined, e.g., by summing free-energy values for hydrogen-bonding and stacking interactions for the nucleotide bases constituting the sequence; free-energy values are predetermined by semi-empirical thermochemical methods; the free energy of melting for a duplex is determined by an equation, e
- the method includes: relating reactivity of a duplex to another free energy parameter, e.g.,T m , by the proportionality constant or function K , wherein K can be determined by determining a free energy parameter, e.g.
- free energies ⁇ Gpj ° of duplex melting, for the duplex formed by each test single stranded nucleic acid molecule e.g., by summing free-energy values for hydrogen-bonding and stacking interactions for the nucleotide bases constituting each potential single strand sequence, wherein such free-energy values are predetermined by semi-empirical thermochemical methods and determining relative composite reaction rates for the selected potential single stranded sequences by means of an equation, e.g., by the following equation,
- the calculated relative binding constants are determined by means of an equation, e.g., the equation,
- K ⁇ and k ⁇ are relative composite rate constants of a reaction for any two DNA sequences I and II, respectively, K* and K ⁇ are relative binding constants for the ligand to any two DNA sequences I and II, respectively, R is the universal gas constant, T is absolute temperature, K is a proportionality constant or function, wherein K is predetermined in accord with the above-recited equations for the ligand and for set sequence length by calculating free energies of melting ⁇ Gr) 0 for at least two preselected DNA flanking sequences if K is a proportionality constant, or at least three if a function, determined in accord with the summing step; a value for K is determined by measuring relative or actual composite rates of reaction or binding constants for synthetic or native DNA sequences containing the preselected DNA flanking sequences and relating the measured relative composite rates of reaction or binding constants to their respective differences in free energy of melting ⁇ G j )° as determined in accord with above-recited equations; and choosing a test molecule to serve as
- Every ligand has a K.
- K relates the reactivity of a nucleic acid to another free energy parameter, e.g.,T m .
- K can be used to relate the reactivity of a nucleic acid to another free energy parameter when the ligand binder is a duplex or a single strand binder, or when the nucleic acid is a single strand or a duplex.
- the invention features, a method for providing a set of nucleic acid primers.
- the set of primers includes: a first single stranded primer which when hybridized to a complementary single stranded molecule, results in a first double stranded (duplex) structure having a first value for a free energy parameter, e.g., a preselected T m or a preselected affinity for a nucleic acid binding ligand, e.g., a DNA polymerase, e.g., Taq polymerase, or which supports the amplification of a product from a region of the first duplex at a first rate of amplification; and a second single stranded primer which when hybridized to a complementary single stranded molecule, results in a second double stranded (duplex) structure having a second value for a free energy parameter, e.g., a preselected T m or a preselected affinity for a nucleic acid binding ligand, e.g., a DNA polymerase, e.g., Taq
- the value of the free energy-parameter formed by the hybridization of a test single stranded nucleic acid molecule to a complementary sequence (formed in step (1)) does not exhibit a preselected relationship with the reference value and a subsequent test single strand nucleic acid molecule is provided by permuting the test single strand nucleic acid molecule.
- steps (1), (2), and (3) are performed to provide a first single stranded nucleic acid sequence which can form a duplex having a preselected value for a free energy parameter, and the cycle of steps (1), (2), and (3), are repeated using the first single stranded nucleic acid as a starting point to provide a second single stranded molecule (which is a permutation of the first) which when hybridized to a complimentary single stranded nucleic acid results in a duplex having a preselected value for a free-energy parameter.
- the second single strand nucleic acid molecule can have a value for a free-energy parameter which is greater than, or less than, the value of the parameter for the first single strand nucleic acid molecule.
- the method further includes providing a second primer by: ( 1 ) determining the value of a free energy-parameter of a duplex formed by the hybridization of a test single stranded nucleic acid molecule to a second (complementary) target sequence;
- the value of the free energy-parameter formed by the hybridization of a test single stranded nucleic acid molecule to a complementary sequence (formed in step (1)) does not exhibit a preselected relationship with the reference value and a subsequent test single strand nucleic acid molecule is provided by permuting the test single strand nucleic acid molecule.
- steps (1), (2), and (3) are performed to provide a first single stranded nucleic acid sequence which can form a duplex having a preselected value for a free energy parameter, and the cycle of steps (1), (2), and (3), are repeated using the first single stranded nucleic acid as a starting point to provide a second single stranded molecule (which is a permutation of the first) which when hybridized to a complimentary single stranded nucleic acid results in a duplex having a preselected value for a free-energy parameter.
- the second single strand nucleic acid molecule can have a value for a free-energy parameter which is greater than, or less than, the value of the parameter for the first single strand nucleic acid molecule.
- the free energy parameter is correlated to with the amplification rate of a product from the duplex, e.g., the DNA polymerase-based amplification in a PCR reaction
- the first single stranded primer when hybridized to a first (complementary) target single stranded molecule, results in a first double stranded (duplex) structure which supports the amplification of a product from a region of the first duplex at a first rate of amplification
- the second single stranded primer when hybridized to a second (complementary) single stranded target molecule, results in a second double stranded (duplex) structure which supports the amplification of a product from a region of the second duplex at a second rate of amplification
- the first amplification rate and the second amplification rate have a preselected relationship with one another, e.g., the first amplification rate, e.g., an amplification rate which is approximately equal with that
- the first and second free energy parameter values and thus the first and second rates of amplification are approximately equal; the values for the first and second free energy parameter, and thus the first and second rates of amplification, are sufficiently similar, such that they allow detection of both amplification products in a single reaction, e.g., a single PCR reaction; the values for the first and second free energy parameter, and thus the first and second amplification rates, are sufficiently similar such that they allow detection of both amplification products after q, wherein q is an integer between 1 and 100, inclusive, cycles of amplification of one of the amplified regions, e.g., the region with the highest or the region with the lowest rate of amplification; the first and second region are on the same molecule; the first and second region are on different molecules; the regions are on one or more preselected molecules.
- the primers are used to amplify a target sequence in an amplification-based reaction, e.g., a DNA polymerase-based reaction, a PCR, a ligase chain reaction, or a cycling probe reaction.
- an amplification-based reaction e.g., a DNA polymerase-based reaction, a PCR, a ligase chain reaction, or a cycling probe reaction.
- the value for a free energy parameter is determined by, beginning at a first base pair of the duplex, determining a value for the free-energy parameter of n base pairs in a window, where n is any integer between 1 and 1,000, inclusive, (preferably or is less than 10, 20, 30, 40, 50, 100, 200, 300, 400, 500, or 1,000) moving the window to another base pair, and determining a value for the free energy parameter of the next window, and repeating the process for some or all of the remaining base pairs of the duplex, preferably, the windows are determined in the linear order in which they appear on the duplex; the free energy ⁇ G ⁇ j° of duplex melting for the duplex formed by a test single stranded nucleic acid molecule is determined, e.g., by summing free-energy values for hydrogen-bonding and stacking interactions for the nucleotide bases constituting the sequence; free-energy values are predetermined by semi-empirical thermochemical methods; the free energy of melting for a duplex is determined by
- ⁇ Gtotal ⁇ i ⁇ Gi,i+i + ⁇ G S ym + ⁇ Gint .
- the method includes: relating the reactivity of a duplex to another free energy parameter, e.g.,T m , by the proprtionality constant or function K , wherein K can be determined by determining a free energy parameter, e.g.
- free energies ⁇ Gr)° of duplex melting, for the duplex formed by each test single stranded nucleic acid molecule e.g., by summing free-energy values for hydrogen-bonding and stacking interactions for the nucleotide bases constituting each potential single strand sequence, wherein such free-energy values are predetermined by semi-empirical thermochemical methods and determining relative composite reaction rates for the selected potential single stranded sequences by means of an equation, e.g., by the following equation,
- the calculated relative binding constants are determined by means of an equation, e.g., the equation,
- K* and K ⁇ are relative composite rate constants of a reaction for any two DNA sequences I and II, respectively, K* and K ⁇ are relative binding constants for the ligand to any two DNA sequences I and II, respectively, R is the universal gas constant, T is absolute temperature, K is a proportionality constant or function, wherein K is predetermined in accord with the above-recited equations for the ligand and for set sequence length by calculating free energies of melting ⁇ Gj) 0 for at least two preselected DNA flanking sequences if K is a proportionality constant, or at least three if a function, determined in accord with the summing step; a value for K is determined by measuring relative or actual composite rates of reaction or binding constants for synthetic or native DNA sequences containing the preselected DNA flanking sequences and relating the measured relative composite rates of reaction or binding constants to their respective differences in free energy of melting ⁇ Grj 0 as determined in accord with above-recited equations; and choosing a primer having a DNA flanking sequence
- Every ligand has a K.
- K relates the reactivity of a nucleic acid to another free energy parameter, e.g.,T m .
- K can be used to relate the reactivity of a nucleic acid to another free energy parameter when the ligand binder is a duplex or a single strand binder, or when the nucleic acid is a single strand or a duplex.
- the primer sequence does not hybridize with any other primer.
- the method further includes using the primers to detect the presence or absence of a target sequence or sequences in, e.g., a PCR reaction; the method further includes contacting the primers of the set with a sample, e.g., in a PCR reaction, and measuring relative or actual composite reaction rates of amplification, or detecting the re ⁇ generation of amplification products, by any method suited for the purpose, including e.g., gel techniques, spectroscopic methods, electrochemical methods, or biochemical assay methods; the method further includes choosing at least one set of primers with approximately equal calculated relative composite reaction rates for amplifying, or generating amplification products for, at least two different regions contacting the primers of the set with a sample, and detecting the presence of the regions in, e.g., a PCR reaction.
- the method further includes detecting the presence or absence of a target sequence or sequences, which if present in a subject indicates that the subject is suffering from or predisposed to an infection (e.g., septicemia) by an organism or virus related to the target sequence or sequences, e.g., a protozoan, viral, bacterial, or yeast sequence.
- an infection e.g., septicemia
- the method further includes detecting the presence or absence of a target sequence or sequences, which if present in a subject indicates that the subject is suffering from or predisposed to a disorder, e.g., and inherited disorder, related to the target sequence or sequences.
- a target sequence or sequences which if present in a subject indicates that the subject is suffering from or predisposed to a disorder, e.g., and inherited disorder, related to the target sequence or sequences.
- the method includes: choosing at least one set of DNA primers with approximately equal calculated relative composite reaction rates for amplifying, or generating amplification products for, at least two different target sequences and using the DNA primers to detect the target sequences, wherein the calculated relative composite reaction rates fall within a predefined deviation about a mean relative composite reaction rate; using at least one set of DNA primers for two different target regions to detect the presence or absence of the target regions, which if present indicates that a subject is suffering from a disease or diseases related to the target sequence or sequences, which comprises combining aliquots of at least one set of DNA primers with an analytical unknown sample which may or may not contain a target sequence or sequences, performing the amplification reaction to generate amplified concentrations or amplification products of the target sequence or sequences, if present, and observing by any suitable qualitative or quantitative method the presence or absence of, the preselected or native DNA sequence or sequences.
- the invention provides a method of detecting the presence or absence of a nucleic acid, e.g., a DNA sequence or sequences corresponding to a disease causing organism or virus, e.g., an agent for an infectious disease, e.g., a viral agent, e.g., human immunodeficiency virus, which includes: providing a set of DNA primers which amplify, or generate amplification products for, at least two different regions from the corresponding nucleic acid sequence at approximately equal rates, and measuring relative or actual composite reaction rates of amplification or generation of amplification products using the nucleic acid primers by any method suited for the purpose; choosing at least one set of nucleic acid primers with approximately equal calculated relative composite reaction rates for amplifying, or generating amplification products for, at least two different regions from the corresponding nucleic acid sequence and using the nucleic acid primers to detect target sequences, wherein the calculated relative composite reaction rates fall within a predefined deviation about a mean relative composite reaction rate
- nucleic acid primers e.g., human immunodeficiency virus
- a sample which may or may not contain the nucleic acid sequence or sequences
- performing the amplification reaction to generate amplified concentrations or amplification products of the nucleic acid sequence or sequences, if present, and observing by any suitable qualitative or quantitative method the presence or absence of, the nucleic acid sequence or sequences corresponding to the organism or virus, wherein suitable methods include gel techniques, spectroscopic methods, electrochemical methods, or biochemical assay methods, thereby detecting the presence or absence of the nucleic acid sequence or sequences corresponding to the organism or virus.
- the invention features, a set of primers, or a reaction mixture, including: a first single stranded primer which when hybridized to a complementary single stranded molecule, results in a first double stranded (duplex) structure having a first value for a free energy parameter, e.g., a preselected T m or a preselected affinity for a nucleic acid binding ligand, e.g., a DNA polymerase, e.g., Taq polymerase, or which supports the amplification of a product from a region of the first duplex at a first rate of amplification; and a second single stranded primer which when hybridized to a complementary single stranded molecule, results in a second double stranded (duplex) structure having a second value for a free energy parameter, e.g., a preselected T m or a preselected affinity for a nucleic acid binding ligand, e.g.,
- the reaction mix includes a target sequence and: one or both of a primer and the target sequence are DNA; one or both of a primer and the target sequence are RNA; the target sequence is RNA and the primer is DNA; a primer is a single stranded probe; the target sequence which is to be detected or amplified is a naturally occurring sequence, e.g., a genomic molecule, or chromosome, e.g., a viral, bacterial, plant, or animal nucleic acid; a primer is a synthetic, purified natural, genetically engineered, or recombinant DNA or RNA molecule, and the target sequence is a naturally occurring nucleic acid, e.g., a genomic molecule, or chromosome, e.g., a viral, bacterial, plant, or animal nucleic acid; the reaction mix includes nucleic acid binding ligand, e.g., a ligand which amplifies the target, e.g., DNA polymerase e.
- a target nucleic acid is at least lOx bases in length, wherein x is an integer between 1 and 1,000, inclusive, e.g., at least 10, 20, 30, 40, 50, 100, 200, 300, 400, or 500, base pairs in length; a target nucleic acid is less than lOx bases in length, wherein x is an integer between 1 and 1,000, inclusive, e.g., less than 10, 20, 30, 40, 50, 100, 200, 300, 400, or 500, base pairs in length; a primer is at least x bases in length, wherein x is an integer between 1 and 500, inclusive, e.g., at least 10, 20, 30, 40, 50, 100, 200, 300, or 400 base pairs in length; a primer is less than x bases in length, wherein x is an integer between 1 and 500, inclusive, e.g., less than least 10, 20, 30, 40, 50, 100, 200, 300, or 400 base pairs in length; a primer is less than x bases in length, wherein x is an integer
- the invention features a method of predicting the relative susceptibility of a site on a nucleic acid duplex to perturbation.
- the method includes: determining the value of a free energy-parameter of a duplex which includes or flanks the site, the value for the free energy parameter being predictive of the susceptibility of the site to perturbation.
- the method further includes, providing a nucleic acid sample including the site from a subject, and determining if there is a mutation at the site, a mutation at the site being indicative of risk of a disorder, e.g., a neoplastic disorder.
- the site is: a base pair; a plurality of base pairs, e.g., p base pairs wherein p is an integer between 1 and 1,000; the site is less than 10, 20, 30. 40, 50, 100, 200, 400, 500, or 1,000 base pairs in length.
- the value for a free energy parameter is determined by, beginning at a first base pair of the duplex, determining a value for the free-energy parameter of n base pairs in a window, where n is any integer between 1 and 1,000, inclusive,
- the windows are determined in the linear order in which they appear on the duplex;
- the free energy ⁇ Gj)° of duplex melting for the duplex which includes or flanks the site is determined, e.g., by summing free-energy values for hydrogen-bonding and stacking interactions for the nucleotide bases constituting the sequence; free-energy values are predetermined by semi-empirical thermochemical methods;
- the free energy of melting for a duplex is determined by an equation, e.g., by the equation:
- the method includes: relating the reactivity of a duplex to another free energy parameter, e.g.,T m , by the proprtionality constant or function K , wherein K can be determined by determining a free energy parameter, e.g.
- free energies ⁇ Grj° of duplex melting, for the duplex formed by each test single stranded nucleic acid molecule e.g., by summing free-energy values for hydrogen-bonding and stacking interactions for the nucleotide bases constituting each potential single strand sequence, wherein such free-energy values are predetermined by semi-empirical thermochemical methods and determining relative composite reaction rates for the selected potential single stranded sequences by means of an equation, e.g., by the following equation,
- the calculated relative binding constants are determined by means of an equation, e.g., the equation, ⁇
- K ⁇ and k ⁇ are relative composite rate constants of a reaction for any two DNA sequences I and II, respectively, K.I and K.H are relative binding constants for the ligand to any two DNA sequences I and II, respectively, R is the universal gas constant, T is absolute temperature, K is a proportionality constant or function, wherein K is predetermined in accord with the above-recited equations for the ligand and for set sequence length by calculating free energies of melting ⁇ Gj)° for at least two preselected DNA flanking sequences if K is a proportionality constant, or at least three if a function, determined in accord with the summing step; a value for K is determined by measuring relative or actual composite rates of reaction or binding constants for synthetic or native DNA sequences containing the preselected DNA flanking sequences and relating the measured relative composite rates of reaction or binding constants to their respective differences in free energy of melting ⁇ G j) ° as determined in accord with above-recited equations.
- Every ligand has a K.
- K relates the reactivity of a nucleic acid to another free energy parameter, e.g.,T m .
- K can be used to relate reactivity of a nucleic acid to another free energy parameter when the ligand binder is a duplex or a single strand binder, or when the DNA is a single strand or a duplex.
- the nucleic acid duplex is a nucleic acid sequence from an organism or virus which is the agent of a disease, e.g., an agent of an infectious disease, e.g., an HIV sequence, or in the case of a single stranded virus, the viral sequence hybridized to a complementary sequence; the method further comprises selecting a base pair within the region susceptible to perturbation and expressing an amino acid with an amino acid change resulting from a mutation in the region, and preferably making an antibody to the mutant protein.
- a disease e.g., an agent of an infectious disease, e.g., an HIV sequence
- the method further comprises selecting a base pair within the region susceptible to perturbation and expressing an amino acid with an amino acid change resulting from a mutation in the region, and preferably making an antibody to the mutant protein.
- the site is a nucleic acid sequence which when subject to perturbation, e.g., mutation, results in a disorder, or in an increased risk for the disorder and: the disorder is a neoplastic disorder; the disorder is manifest in the individual tested or in the individual's offspring; the method further includes determining if the site in an individual is more perturbation sensitive than a reference site, thereby providing a measure of the susceptibility of the individual or the individual's offspring to the disorder.
- perturbation e.g., mutation
- the invention features a method of constructing a map of the relative susceptibility to perturbation of a plurality of sites in a region of a nucleic acid duplex.
- the method includes:
- the value of the free-energy parameter can be determined, e.g., empirically, semi- empirically, or by calculation, e.g., by a method described herein, or by any method known to those in the art.
- the site is: a base pair, a plurality of base pairs, e.g., n base pairs wherein n is an integer between 1 and 1,000; the site is less than 10, 20, 30. 40, 50, 100,
- a region is: all or part of a gene; a plurality of sites, e.g., p sites wherein p is an integer between 1 and 1,000; is less than 10, 20, 30. 40, 50, 100, 200, 400, 500, or 1,000 sites.
- the value for a free energy parameter is determined by, beginning at a first base pair of the site, determining a value for the free-energy parameter of n base pairs in a window, where n is any integer between 1 and 1,000, inclusive, (preferably or is less than 10, 20, 30, 40, 50, 100, 200, 300, 400, 500, or 1,000) moving the window to a subsequent base pair, and determining a value for the free energy parameter of the that window, and repeating the process for some or all the remaining base pairs in the site, preferably, the windows are determined in the linear order in which they appear in the site; the free energy ⁇ Grj° of duplex melting for the duplex formed by a single stranded sequence is determined, e.g., by summing free-energy values for hydrogen-bonding and stacking interactions for the nucleotide bases constituting the sequence; free-energy values are predetermined by semi-empirical thermochemical methods; the free energy of melting for a duplex is determined by an equation, e.g.
- ⁇ Gtotal ⁇ i ⁇ Gi 5 i+l + ⁇ G sym + Gint •
- the method includes: relating reactivity of a duplex to another free energy parameter, e.g.,T m , by the proprtionality constant or function K , wherein K can be determined by determining a free energy parameter, e.g.
- free energies ⁇ Gpj ° of duplex melting, for the duplex formed by each test single stranded nucleic acid molecule e.g., by summing free-energy values for hydrogen-bonding and stacking interactions for the nucleotide bases constituting each potential single strand sequence, wherein such free-energy values are predetermined by semi-empirical thermochemical methods and determining relative composite reaction rates for the selected potential single stranded sequences by means of an equation, e.g., by the following equation,
- the calculated relative binding constants are determined by means of an equation, e.g., the equation,
- K ⁇ and K ⁇ are relative composite rate constants of a reaction for any two DNA sequences I and II, respectively, K ⁇ and K ⁇ are relative binding constants for the ligand to any two DNA sequences I and II, respectively, R is the universal gas constant, T is absolute temperature, K is a proportionality constant or function, wherein K is predetermined in accord with the above-recited equations for the ligand and for set sequence length by calculating free energies of melting ⁇ GQ 0 for at least two preselected DNA flanking sequences if K is a proportionality constant, or at least three if a function, determined in accord with the summing step; a value for K is determined by measuring relative or actual composite rates of reaction or binding constants for synthetic or native DNA sequences containing the preselected DNA flanking sequences and relating the measured relative composite rates of reaction or binding constants to their respective differences in free energy of melting ⁇ Gr j ° as determined in accord with above-recited equations.
- Every ligand has a K.
- K relates the reactivity of a nucleic acid to another free energy parameter, e.g.,T m .
- K can be used to relate reactivity of a nucleic acid to another free energy parameter when the ligand binder is a duplex or a single strand binder, or when the DNA is a single strand or a duplex.
- the nucleic acid duplex is a viral sequence, or in the case of a single stranded virus, the viral sequence hybridized to a complementary sequence; the nucleic acid sequence is an HIV sequence.
- Providing includes, synthesizing, isolating, determining, designing, selecting, or supplying.
- a reference or preselected sequence is any of: a naturally or a non-naturally occurring nucleic acid sequence, e.g., a naturally occurring sequence which binds a ligand; a sequence which has an approximately similar ⁇ Grj° and length as a test sequence; a sequence which is of equivalent type (RNA or DNA) and of approximately the same length as a test sequence; a sequence with approximately the same GC:AT composition as a test sequence; a sequence with the ⁇ Grj° of a nucleic acid, which in nature binds to a ligand.
- a reference value for a parameter is any of : the value for that parameter for a preselected or reference sequence; or a value chosen as a desired, preferred, or optimal value for a duplex.
- a preselected relationship between two values can refer to any of situations where the a first or determined value is less than, greater than, or approximately equal to a second or reference value.
- a preselected value is a value with a preselected relationship with a reference value.
- a free energy parameter is a parameter related to, (e.g., proportional to, or correlated to, or inversely correlated to) the free energy of a duplex nucleic acid, e.g., to the free energy of melting or formation of a duplex (e.g., the free energy of melting, ⁇ Gr)°), to stability or resistance to melting, to affinity for a nucleic acid-binding ligand, to a relative composite reaction rate with a ligand, or to the susceptibility of the duplex to perturbation.
- Perturbation refers to a change in the primary, secondary, or tertiary structure of a nucleic acid or to an interaction of the nucleic acid with a ligand and includes: melting; ligand binding; mutagenesis; intercalation of a compound into the duplex; the breaking or forming of a covalent or non-covalent bond between an atom of the nucleic acid and another atom, e.g., the insertion of a base, the deletion of a base, the change in the identity of a base, a chromosomal rearrangement, e.g., an inversion; or a chemical modification of the nucleic acid, e.g., by methylation or alkylation.
- Permuting a sequence refers to changing the sequence by any of: altering the chemical nature of a base in the sequence, e.g., changing the identity of the base, e.g., by substituting a T for an A, G, or C; by adding a base or deleting a base. Permutation can proceed by making a change at a single base, or by making changes at a plurality of bases.
- Primer refers to a nucleic acid which when hybridized to a complementary single strand nucleic acid, either or both, allows detection of the complementary strand, or promotes a reaction between the primer, the complementary strand, the duplex formed between the two, and a nucleic acid binding ligand.
- a nucleic acid binding ligand refers to one or more of: a compound which binds to a nucleic acid in a sequence-specific way (e.g., a sequence specific cleavage enzyme, such as a restriction endonuclease, including EcoRI, Haelll, and Bgll, or an enzyme or other molecule which binds to a specific sequence, e.g., molecules which modulate the expression of a product encoded by a nucleic acid) or in a sequence-non-specific way (e.g., DNasel or micrococcal nuclease); a protein; an enzyme; an enzyme or other molecule (and agonists or antagonists thereof) which alters the structure of a nucleic acid to which is binds, e.g., by breaking or forming a covalent or non-covalent bond, e.g., a hydrogen bond, between an atom of the nucleic acid and another atom, e.g.,
- K can be used in methods of the invention in which the reactivity of a duplex to a ligand is of interest or is to be determined. Methods of the invention are concerned with the general process ki k 2
- E any enzyme
- D is a given DNA sequence
- ED is the complex between the enzyme and DNA
- P is the product(s) produced the action of E on D.
- the overall rate of this reaction, k c can be expressed as
- k c the composite second order rate constant for the reaction (two reactants and one product)
- kl forward rate constant for the first step
- k_ ⁇ reverse rate constant for the first step
- k the rate constant for catalysis
- Kj kj/k.1 the equilibrium constant for forming the bound complex (e.g.,
- K a constant that relates the composite activation free energy to the free energy of melting the duplex. It follows that even if all that is known is the composite rate for two different DNA sequences, k c and k c ' , respectively and (independently) the melting free energies of the two duplexes, K, may be determined directly viz (substituting into (e) and subtracting)
- K RTln[k c '/k c ]/( ⁇ G D ° - ⁇ G D 0 ⁇ ) ⁇
- free-energy profiles of a 1635 bp restriction fragment from pBR322 are constructed. Melting free-energies are also calculated for seven short duplex DNA oligomers with model sequences and lengths of 12, 16 and 20 bps. Results of optical and calorimetric melting curves of the seven DNA oligomers collected in 115 mM Na + solvent are reported. Analysis of these results allows an evaluation of thermodynamic parameters that govern the melting transitions of the DNAs. Differences between calculated and experimentally determined free-energies provide evaluations of the free energy of duplex initiation, ⁇ Gint. f° r DNAs 12 to 20 bp long.
- Double helical DNA structure is maintained by a number of forces. Among these are the strong Coulombic interactions between phosphates along and across the backbone, hydrogen bonding between bps across the helix axis, stacking interactions between bps along one strand and across the helix axis, and a multiplicity of interactions with charged and polar solvent components. Presently ,the understanding of these interactions makes it difficult to construct a realistic atomic model that correctly simulates the helix-coil or melting transition in DNA. In consolation, melting behavior can be reasonably modeled with parameterized statistical thermodynamic treatments.
- DNA stability can be expressed as a number weighted sum of the individual energies of two components, these being the energies of A'T (T'A) and G'C (C'G) bps.
- this energy the H-bond energy
- ⁇ G H -bond ( i ) ⁇ S AT N AT T AT + ⁇ SQCNGCTGC (1)
- N A ⁇ and NQQ are the numbers of A'T and G'C bps in the sequence and T A ⁇ and TQC are the average melting temperatures of A'T (T'A) and G'C (C'G) bps.
- the dependence of t on solvent ionic strength is included in the values of T AT or T GC - They have been empirically evaluated from melting curve analysis of a variety of DNAs collected as a function of solvent environment. Relationships that describe the dependence of ⁇ and T Q C on [Na + ] were first reported by Frank-Kamenetski [111] . These are,
- ⁇ HQ- can be determined. Therefore, if DNA is considered to be comprised of only two energetic components, the free-energy can be estimated directly from the sequence by substitution of the appropriate values from eqns (2) , (4) and (5) in eqn (1) .
- n-n sequence dependent energetics in DNA two formats have been presented [cf42] that differ primarily in the manner in which the possible n-n interactions are formally described. Subsequently these formalisms are referred to as the "n-n doublet" and “single bp" formats. Distinguishing characteristics of these approaches, including the different DNA samples and methods of evaluating n-n interactions from analysis of optical melting curves, are presented in the following two sub-sections.
- n-n sequence dependence is considered to arise from the cumulative contributions of the hydrogen bonds and n-n stacking interactions associated with a doublet of two bps.
- the individual contributions of bp hydrogen bonding and stacking are not separately distinguished.
- This model of n-n sequence dependent stability was employed by Breslauer and co-workers [100] , Delcourt and Blake [88] and in the earlier work of Vologodskii et al. [99] and Gotoh and Tagashira [98] .
- Delcourt and Blake evaluated n-n interactions from melting analysis of an entirely different class of DNA molecules. They utilized techniques of molecular biology to construct a variety of plasmid DNAs. From these plasmids relatively long (4000-5000 bps) DNA restriction fragments, whose entire sequence was known, and whose differential melting curves displayed multiple peaks or "fine structure" were isolated. As mentioned earlier such fine structure is attributed to the cooperative melting of individual regions or domains. Locations of melting domains were determined from melting curves of linear plasmids that had been cut with restriction enzymes at different sites. Delcourt and Blake assumed each domain analyzed melted in a 2-state manner and analyzed their melting curves using the more sophisticated multistate statistical thermodynamic theoretical melting model [cf88] .
- SMN exp[( ⁇ S/RT) (T-Tr ⁇ j) ] (7)
- MN th effective melting temperature of doublet MN
- T m transition temperature
- eqns (lOa-lOc) have precisely the form of eqn (8) .
- T N ⁇ HMN/ ⁇ S di
- ⁇ GMN ⁇ S(TMN - T) (12)
- T 's of 35 domains ranging in size from 50 to 620 bps were predicted from the evaluated set of n-n interactions using eqn (8) . Remarkable agreement was obtained between the calculated and observed melting temperatures of these domains with an average deviation between the observed and calculated T m 's of only ⁇ 0.168°C.
- n-n stacking is included with H-bonding in the composite energy of a bp doublet. Energetic contributions from H-bonding and n-n stacking are not individually distinguished. In both studies described so far, only these composite interactions modeled as a doublet were evaluated. Alternatively, n-n stacking and H-bonding contributions to stability can be separately considered and evaluated from melting experiments.
- the free-energy change in forming bp i depends on the type of bp i (A'T or G'C) and establishing stacking interactions with neighboring bps i-1 and i+1.
- ⁇ G is given by
- the ⁇ Gi + ⁇ terms in eqn (14) are actually deviations from the average n-n stacking free-energy specific for each type of n-n stack and can take on ten different values.
- the n-n interactions in this format were recently evaluated by Doktycz et al. [42] from melting studies of a series of DNA dumbbell molecules.
- dumbbells Optical melting curves of the dumbbells were collected in solvents containing 25 mM, 55 mM, 85 mM and 115 mM [Na + ] , 10 mM Phosphate, 1 mM
- N dictated by the self-complementary sequence, is the number of duplex bps that form when the dumbbell collapses from a melted circle to a duplex with single strand loops on both ends.
- N A - ⁇ and NQ . Q are the numbers of A'T and G'C bps in the dumbbell duplex region and T A . ⁇ ' and T G .c' are their average melting temperatures in the dumbbell.
- eqn All parameters required by the left hand side of eqn (15) could be determined from the duplex sequence (N, N A . ⁇ >, NQ.Q) , melting experiments (T m , T A> ⁇ ', TQ-C 1 ) and independent measurements ( ⁇ S) .
- the ⁇ G s values were the unknowns to be solved from the information supplied.
- eqn (15) provided 17 linear equations from which to determine the 10 ⁇ G s 's. Provided at least 10 of the 17 available equations were linearly independent, the system of equations would be overdetermined and therefore soluble for 10 possible unique values of the ⁇ G s 's.
- a non-unique set of the ⁇ G s 's could be determined using singular value decomposition (SVD) [124] . Because the values determined by SVD are not unique, they cannot be meaningfully compared with one another or with values obtained by different researchers. As such the values given in Table 1 are in fact non-unique. However, the non-unique values can be appropriately summed to yield the total deviation from average stacking for any duplex sequence.
- SVD singular value decomposition
- n-n interactions were presented as combinations of the deviations from average stacking for the 5'-3' bp doublets, ⁇ G . Because these combinations are linearly independent, they are unique. Titratable changes in these ⁇ Gi values with changing salt environment were observed.
- the singlet values obtained from dumbbells must be transformed into the doublet format.
- the single bp and doublet formats can be united by defining an effective melting temperature, TMN, of the doublet comprised of the neighboring bps M and N.
- Base pairs M and N each have individual melting temperatures T and T_ $ equal to ⁇ or TQC and a contribution from the stacking interactions between them. This stacking interaction is written as the deviation due to n-n stacking, °f T M N from the average melting temperatures of bps M and N, i.e.
- ⁇ TMN ⁇ GMN/ ⁇ SMN ( 17 )
- ⁇ G N ⁇ S [ (T M + T N ) /2 + ⁇ G MN ⁇ S - T] (18)
- the values in columns B and C are quite comparable and the hierarchy of the values is precisely the same.
- the remainder of the values in columns B and C differ by less than 124 cal/mol.
- the values in column A evaluated at a much higher Na + concentration, where DNA is inherently more stable are larger in magnitude than the values in columns B and C.
- Fig 3 Sequences of the seven molecules are shown in Fig 3.
- the set is comprised of two 12-mers, three 16-mers and two 20-mers.
- Each of the DNA strands comprising the duplexes are self-complementary.
- the number of A'T (T'A) bps is the same, only the distribution of A'T and T'A bps differs for fragments of the same length. Therefore, any differences in stability between two fragments of the same size can be attributed to differences in the n-n sequences of the fragments.
- Another feature of these sequences is that the central-most four bp sequence is the recognition site of both restriction enzyme Alu I and the drug actinomycin D.
- the length of the molecules are such that their melting temperatures conveniently fall in a range that allows reliable acquisition and analysis of experimental melting curves.
- the sequences are short enough that their melting transitions may be accurately modeled with a two-state, all-or-none model.
- ⁇ G S ym is a symmetry correction that accounts for the degeneracy in self-complementary versus non-self-complementary sequences.
- ⁇ Sgym -1.4 eu.
- Table 3 readily reveals for the three n-n sets, the calculated higher stability of the (AA) n sequences over the (AT) n sequences.
- the 16 bp sequence AA(AT) 2 (SEQ ID NO: 5) has a calculated partial free-energy intermediate between those of the (AA) 3 (SEQ ID NO: 2) and (AT) 3 (SEQ ID NO: 1) 16 bp sequences.
- Magnitudes of the values in columns B and C are comparable.
- the values in column A are more negative ranging from -15.7 to -37.1 kcal/mol and are 20-40% higher in magnitude than the corresponding values in column B (-12.6 to -20.4 kcal/mol), and 15-35% higher than the values in column C.
- the total free-energy, ⁇ GT must also include the free-energy of helix initiation, ⁇ Gi n t.
- ⁇ Gi n accounts for the added difficulty of forming the first bp initiating the duplex compared to the subsequent formation of all other bps.
- Absorbance versus temperature profiles were collected for each of the molecules at heating and cooling rates of 60°C per hour over the temperature range from 5 to 85°C. A data point was collected approximately every 0.1 °C. For each sample, melting curves were collected as a function of total strand concentration, Op/ over the 200 fold range from approximately 500 nM to 100 ⁇ M. Absolute absorbance readings ranged from 0.08 OD to 1.3 OD. Optically matched quartz cuvettes with 1 and 0.1 cm path lengths were employed. All melting curves were entirely reversible upon cooling at the same rate.
- sample and reference buffer solutions were filtered through 0.45 ⁇ M pore size filters. At least 25 to 100 OD units (absorbance at 260 nm in a 1 cm pathlength cuvette) of DNA solution was melted in the 1.2 ml reaction chamber of the calorimeter. DNA strand concentrations estimated from extinction coefficients determined by the n-n method [130] , varied from 3 to 10 mM. These concentrations were from two to 10 times higher than in optical melting experiments.
- Calorimetric data was collected as the change in excess heat capacity, ⁇ Cp, versus temperature, T.
- the average buffer base line determined from eight scans of the buffer alone was subtracted from these curves.
- the calorimetric transition enthalpy, ⁇ H ca ⁇ , was determined from the area under the base line corrected ⁇ Cp vs. T curve, viz.
- the temperature of the maximum value of the baseline corrected ⁇ Cp versus temperature curve was the transition temperature, T m .
- the calorimetric transition entropy, ⁇ S ca l. was also determined from the baseline corrected ⁇ Cp as,
- Table 5 Values of ⁇ Gint determined from differences of appropriate values in Tables 3 and 4 are given in Table 5.
- Table 5 indicates ⁇ G n t has the opposite sign of ⁇ Gp, revealing (as expected) helix nucleation makes a destabilizing contribution to the total free-energy of a duplex. Examination of the values in Table 5, reveals that ⁇ Gint is essentially independent of duplex length. However, magnitudes and standard deviations of the averages are different.
- the average of the values in column A is 15.1 ⁇ 3.9 kcal/mol compared to 6.8 ⁇ 1.2 kcal/mol for column B and 8.5 + 1.0 kcal/mol for column C.
- the free-energy of helix initiation, ⁇ G n t (N) is related to the helix nucleation parameter, ⁇ (N) [4,131] as,
- DNAs with 12, 16 and 20 bps is consistent with similar findings for short duplex DNAs and RNAs [100,122] .
- n-n values were used to calculate energy profiles for the 1635 bp Hinfl fragment from plasmid pBR322 [128] and calculate free-energies of seven duplex DNAs ranging in length from 12 to 20 bps. Calculated results were compared with results from experimental analysis of melting transitions of the seven model DNA duplex oligomers. In the next section, results of rates of attack of these same model oligomers by several ligands are presented.
- each of these tetramers could have a different binding constant for the ligand.
- any given tetramer would occur once every 256 bps.
- 256 bps of DNA would be required to examine just 70% of the total potential pool of tetramer binding sites. In practice little attention has been paid to this issue.
- a second complicating factor for ligand binding studies is difficulty of determining ligand stoichiometry for many DNA sequences. For any equilibrium process, assessment of binding stoichiometry is inherently difficult. In the case of a lattice of potential binding sites (which can be overlapping and nonunique) , stoichiometry determination is further complicated. For example, if binding to a single GC site influences binding at a second GC site directly adjacent to the first (cooperativity) , then a sequence such as 5'-GCGC-3' could appear to be a "better” or "worse" binding site for the ligand based solely on an assumed stoichiometry.
- Footprinting was first applied to describe differences in partial digestion patterns of restriction fragment DNAs exposed to the ubiquitous DNA cutter DNAse I in the presence and absence of a binding ligand [155] . Footprinting provides an elegant and relatively simple means for identifying DNA sequences specifically bound by ligands. Quantitative applications of this procedure (and its variations) to assess protein/DNA interactions were recently reviewed [144] . Of the newer sequencing methodologies available for characterization of ligand/DNA binding, footprinting techniques are the most widely used. In a classical DNAse I footprinting experiment end-labeled duplex DNA is first incubated with the ligand to be probed and then subjected to partial digestion by DNAse I.
- DNA digestion products obtained from separate reactions conducted in the presence and absence of ligand are then run in adjacent lanes of a denaturing polyacrylamide gel. After electrophoresis each lane contains a "ladder" of products.
- an interrupted ladder pattern results because the site where the ligand binds is sterically blocked from accessibility to the enzyme.
- footprinting is a competition assay; both the DNA footprinting (cleaving, modifying) reagent and the binding ligand compete for the same DNA sequence(s) . If the ligand is bound at a given DNA sequence then the cleaving agent cannot make a cut and a footprint is generated. Alternatively, if the cleaving agent completely outcompetes the ligand for a particular sequence, no footprint is produced. For this reason, an implicit assumption in any quantitative footprinting experiment must be that the binding constant of the ligand/substrate complex far exceeds that of the cleaving agent/substrate complex. In practice, to ensure this requirement is met at some point, the concentration of the ligand under study is increased until a specific footprint is observed.
- ligand binding is driven by the ligand concentration. From this procedure qualitative rankings of which sequences, of those available in the reaction mixture, are bound most efficaciously by the ligand can be obtained.
- the quantitative analysis of footprinting experiments can be quite complex depending on the ligand under study. In any quantitative footprinting experiment the binding constants of both the cleaving (or modifying) footprinting reagent and ligand for a specific DNA sequence will make some contribution (even if small enough to ignore) to the measured thermodynamic binding data. With this realization two operational classes of DNA ligands can be delineated. First, there are ligands that display DNA binding affinities that are (under conditions of a given experiment) orders of magnitude greater than the footprinting reagent.
- the second class of ligands are those that bind with affinities comparable to the footprinting reagent. For relatively complex DNA sequences such as restriction fragments, extraction of the true binding constant for this type of ligand at a given DNA sequence is a more arduous task.
- These ligands (examples are antibiotics and antitumor agents) generally display specificity for many DNA sites, making it virtually impossible to accurately determine free ligand concentrations by the site bound method (described above) . Accurate determination of the free-ligand concentration would require simultaneous determination of the extent of binding to all bps in the restriction fragment, as well as the stoichiometries at all possible bound positions at any given point in a titration.
- DNAse I enhancements Before presenting DNAse I enhancements as secondary ligand binding effects more clarification is required. To understand the causes of DNAse I enhancements one must first examine the kinetic order of the DNAse I reaction in a typical experiment. DNAse I is known to display a typical hyperbolic substrate dependence with respect to single strand cleavage
- footprinting reactions can be extremely helpful in qualitatively locating ligand binding positions.
- the methodology can provide quantitative binding data for ligands that display high binding affinities for their DNA sites.
- additional factors must be considered before reliable binding constants can be obtained.
- flanking sequences likewise transmit effects back to the actinomycin D binding site in the center?
- actinomycin D is capable of discriminating between two sequence isomers, is this a general property of all DNA binding ligands or a characteristic unique only to actinomycin D?
- the labeled duplex concentration was 95 + 15 nM. Labelled duplexes were pre-annealed and no hairpins were detected by native polyacrylamide gels. Reactions were performed for varying lengths of time, but never exceeding the time where more than 50% of total substrate was cleaved. Rate measurements for each duplex were repeated at least twice, and each independent rate measurement employed independently labelled duplex.
- the fraction of duplex remaining as full length was determined after separation of cleaved product from full length strands on 7.0 M urea polyacrylamide gels by autoradiography. Full length molecules remaining were excised from the gel and analyzed by direct Cherenkov counting. Consequently, each time point represents the average fraction remaining (relative to control experiments with no enzyme, executed in parallel) determined from at least two independent cleavage experiments.
- Rate constants were determined by linear least squares fits to the f c (t) versus time data. The linear fits are shown for all seven duplexes. Rates obtained from the slopes in Fig 8 are listed in Table 6 along with correlation coefficients of the linear fits. Note, R values in no case are lower than 0.95 indicating that the precision of the data obtained by the method employed is reasonably good.
- Fig 9 the observed rate constants for first strand cleavage, k 0 b s , are plotted versus duplex length.
- k Q bs is tne observed relative rate of enzyme first strand cleavage of the duplexes under first order kinetic conditions.
- Fig 10 further suggest a linear relationship between the activation free-energy for Alu I first strand cleavage, ⁇ G ++ , of a particular length duplex DNA substrate and the free-energy of melting the duplex, ⁇ GD, i.e.
- Ki exp(- ⁇ G ⁇ /RT) is the equilibrium constant for binding.
- k c A c exp( ⁇ G ++ C /RT) is the subsequent rate constant for first strand cleavage as defined above.
- K(N) is a unitless function of sequence length but not sequence composition.
- K(N) relates the activation free-energy for enzyme reactivity to the free-energy of duplex melting. It remains to be fully explained how binding of a duplex binding ligand, such as Alu I restriction enzyme, could be dependent on the stability of non-contacted bps in the vicinity of the binding site. From eqn (31) it is clear that all ligands which preferentially bind to DNA duplexes (as opposed to single strands) are in fact directly in the pathway of duplex formation. Consider the significant (first two) steps in the reaction in eqn (31) .
- duplex DNA concentration is determined by the equilibrium between duplex and single strands, a classical case of a coupled equilibrium exists.
- a similar situation has been utilized to determine binding constants of DNA binding ligands (actinomycin D) from observation of the net elevation of T m in the presence of bound ligands [cf187,188] .
- a single binding site on a "short" DNA duplex the equilibrium binding constant can be written as a function of the duplex melting equilibrium, i.e.
- Ki ([E'D]K D )/([S ⁇ ] [S 2 ] [E]) (35)
- the binding constant of the ligand for this sequence will be higher if this second duplex is less stable than the first duplex or lower if the opposite is true.
- the observed binding constant is composed of an intrinsic primary binding component and a flanking sequence secondary binding component. Consequently, for two sequences possessing the same binding site for a common ligand only the flanking sequence stability alters the binding constant. Again this is inferred from Fig 10.
- Ki and Ki' with the appropriate primed quantities substituted in eqn (35) .
- Ki'/K! ( [E'D] 'K D ')/([E'D]K D ) (36)
- ⁇ (N) RTln(kobs ⁇ -obs)/( ⁇ G D - ⁇ G D ') (40)
- K is the equilibrium constant for binding and k c is the rate constant for first bond cleavage producing the bound, cleaved species, [E'DNA] ++ .
- the pre-exponential factor, A kgT/h, includes frequency and non-ideality factors associated with formation of the transition state.
- K A .k c is analogous to the familiar quantity k ca t/ m from classical Michaelis-Menten analysis, it avoids two difficulties associated with the Michaelis-Menten scheme [185] .
- k ca t in Michaelis-Menten analysis is the catalytic constant for the entire reaction and may reflect rate limiting steps after initial bond cleavage (i.e. second strand recognition and cleavage reactions [cf195] ) .
- K m is not a true equilibrium constant for binding of the enzyme to DNA.
- Supposing primary recognition and binding comprise the predominant energetic contributions for sequence specific interactions
- the observed affinity of a ligand for a specific primary sequence should only be modulated by the free-energy of the flanking sequences. If so, it should be possible to estimate the degree of binding modulation of any ligand by examination of the flanking sequence.
- the extent of secondary sequence modulation would likely depend on the variety of free-energies possible from the composition and arrangement of the flanking sequences, it is not yet possible to predict secondary sequence modulation.
- effects of certain specific sequences can be ascertained from an empirical data set collected for several well defined DNA sequences and a given ligand. In any experiment, the extent of secondary modulation must be of a magnitude sufficient to produce a measurable change in primary binding affinity.
- flanking sequences if the primary ligand binding constant is overwhelmingly dominant, modulation by flanking sequences would be expected to be small.
- data available for many ligands, such as restriction enzymes reveals the primary sequence or intrinsic binding constant is small enough so that measurable modulation actually occurs.
- a constant ratio of Alu I cleavage rates was observed for flanking sequences having two different AT stacking patterns. This ratio was independent of duplex substrate length from 12 to 20 bps.
- Point (3) is counter-intuitive. It seems logical that any model for binding site modulation by flanking sequences should include a distance dependence. That is, a ligand's relative binding affinity for two different sequences containing the same binding site, but differing at a single base residue in the flanking sequences, should be more greatly affected the closer the bp change is to the primary binding site. As demonstrated by comparison of the Alu I cleavage rates of the 16 bp isomers, this is not the case. Within experimental resolution, adding AA stacks to the end of the duplexes has the same effect as adding AA stacks closer to the Alu I site. Failure to observe a distance dependence immediately suggests the molecules examined are not of sufficient length to allow detection of the suspected distance effects. In this sense the results do not provide a determination of the length or "window" of DNA sequence over which Alu I cleavage is measurably modulated. Even so, results do reveal that this distance can be at least eight bps.
- kobs composite rate constant for cleavage k ⁇ adduct ⁇ rate constant for UV induced adduct formation at
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU71739/94A AU691505B2 (en) | 1993-06-17 | 1994-06-16 | Thermodynamics, design, and use of nucleic acid sequences |
EP94920751A EP0752007A4 (en) | 1993-06-17 | 1994-06-16 | THERMODYNAMICS, DESIGN AND USE OF NUCLEIC ACID SEQUENCES |
JP7502945A JPH09502341A (en) | 1993-06-17 | 1994-06-16 | Thermodynamics, design and use of nucleic acid sequences |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7875993A | 1993-06-17 | 1993-06-17 | |
US08/078,759 | 1993-06-17 | ||
US22484094A | 1994-04-08 | 1994-04-08 | |
US08/224,840 | 1994-04-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1995000665A1 true WO1995000665A1 (en) | 1995-01-05 |
WO1995000665A9 WO1995000665A9 (en) | 1995-05-04 |
Family
ID=26760906
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/006799 WO1995000665A1 (en) | 1993-06-17 | 1994-06-16 | Thermodynamics, design, and use of nucleic acid sequences |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0752007A4 (en) |
JP (1) | JPH09502341A (en) |
AU (1) | AU691505B2 (en) |
CA (1) | CA2165163A1 (en) |
WO (1) | WO1995000665A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999042621A3 (en) * | 1998-02-21 | 2000-03-16 | Tm Technologies Inc | Methods for identifying or characterising a site based on the thermodynamic properties of nucleic acids |
WO1999063074A3 (en) * | 1998-06-04 | 2000-04-06 | Tm Technologies Inc | Altering the ligand-binding characteristics of a nucleic acid ligand binding sequence by altering the nucleotide composition of its flanking sequences |
WO1999063077A3 (en) * | 1998-06-04 | 2000-06-29 | Tm Technologies Inc | Compositions of nucleic acid which alter ligand-binding characteristics and related methods and products |
FR2842534A1 (en) * | 2002-07-19 | 2004-01-23 | Inst Nat Sante Rech Med | GENOME-BASED QUANTITATIVE MULTIPLEX AMPLIFICATION AND APPLICATIONS FOR DETECTION OF GENOMIC REMANIATION |
US8575101B2 (en) | 2005-01-06 | 2013-11-05 | Kuros Biosurgery Ag | Supplemented matrices for the repair of bone fractures |
CN114539422A (en) * | 2020-11-25 | 2022-05-27 | 安升(上海)医药科技有限公司 | Construction method and application of multivalent protein drug and vaccine mediated by nucleic acid multimerization |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5618227B2 (en) * | 2009-06-04 | 2014-11-05 | 独立行政法人理化学研究所 | Nucleic acid amplification method and gene mutation detection method |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5011769A (en) * | 1985-12-05 | 1991-04-30 | Meiogenics U.S. Limited Partnership | Methods for detecting nucleic acid sequences |
-
1994
- 1994-06-16 AU AU71739/94A patent/AU691505B2/en not_active Ceased
- 1994-06-16 EP EP94920751A patent/EP0752007A4/en not_active Withdrawn
- 1994-06-16 JP JP7502945A patent/JPH09502341A/en not_active Ceased
- 1994-06-16 CA CA002165163A patent/CA2165163A1/en not_active Abandoned
- 1994-06-16 WO PCT/US1994/006799 patent/WO1995000665A1/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5011769A (en) * | 1985-12-05 | 1991-04-30 | Meiogenics U.S. Limited Partnership | Methods for detecting nucleic acid sequences |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999042621A3 (en) * | 1998-02-21 | 2000-03-16 | Tm Technologies Inc | Methods for identifying or characterising a site based on the thermodynamic properties of nucleic acids |
WO1999063074A3 (en) * | 1998-06-04 | 2000-04-06 | Tm Technologies Inc | Altering the ligand-binding characteristics of a nucleic acid ligand binding sequence by altering the nucleotide composition of its flanking sequences |
WO1999063077A3 (en) * | 1998-06-04 | 2000-06-29 | Tm Technologies Inc | Compositions of nucleic acid which alter ligand-binding characteristics and related methods and products |
FR2842534A1 (en) * | 2002-07-19 | 2004-01-23 | Inst Nat Sante Rech Med | GENOME-BASED QUANTITATIVE MULTIPLEX AMPLIFICATION AND APPLICATIONS FOR DETECTION OF GENOMIC REMANIATION |
WO2004009846A1 (en) * | 2002-07-19 | 2004-01-29 | Inserm | Quantitative multiplex amplificaction on a genomic scale, and applications for detecting genomic rearrangements |
US8575101B2 (en) | 2005-01-06 | 2013-11-05 | Kuros Biosurgery Ag | Supplemented matrices for the repair of bone fractures |
CN114539422A (en) * | 2020-11-25 | 2022-05-27 | 安升(上海)医药科技有限公司 | Construction method and application of multivalent protein drug and vaccine mediated by nucleic acid multimerization |
CN114539422B (en) * | 2020-11-25 | 2024-03-29 | 安升(上海)医药科技有限公司 | Construction methods and applications of multivalent protein drugs and vaccines mediated by nucleic acid multimerization |
Also Published As
Publication number | Publication date |
---|---|
JPH09502341A (en) | 1997-03-11 |
AU691505B2 (en) | 1998-05-21 |
CA2165163A1 (en) | 1995-01-05 |
EP0752007A1 (en) | 1997-01-08 |
EP0752007A4 (en) | 1999-12-22 |
AU7173994A (en) | 1995-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4023766B1 (en) | Method for detecting nucleic acid | |
ES2528253T3 (en) | Methods for the precise determination of sequence data and the position of modified bases | |
KR102592367B1 (en) | Systems and methods for clonal replication and amplification of nucleic acid molecules for genomic and therapeutic applications | |
US11274341B2 (en) | Assay methods using DNA binding proteins | |
US6027884A (en) | Thermodynamics, design, and use of nucleic acid sequences | |
Boskovic et al. | Monitoring G-quadruplex formation with DNA carriers and solid-state nanopores | |
WO2011049955A1 (en) | Deducing exon connectivity by rna-templated dna ligation/sequencing | |
JPH09512428A (en) | Detection of mutations by resorbase cleavage | |
US20150159207A1 (en) | Use of markers including nucleotide sequence based codes to monitor methods of detection and identification of genetic material | |
JP2010527241A (en) | Methods for screening nucleic acids for single nucleotide variations | |
US20150344977A1 (en) | Method And System For Detection Of An Organism | |
US5593834A (en) | Method of preparing DNA sequences with known ligand binding characteristics | |
AU691505B2 (en) | Thermodynamics, design, and use of nucleic acid sequences | |
WO1995000665A9 (en) | Thermodynamics, design, and use of nucleic acid sequences | |
Benight et al. | Sequence context and DNA reactivity: application to sequence-specific cleavage of DNA | |
EP0708839A1 (en) | Improved nucleic acid reactions | |
Kaufmann et al. | An Oligo-Library-Based Approach for Mapping DNA–DNA Triplex Interactions In Vitro | |
Lu et al. | Interaction of drugs with branched DNA structures | |
CN114107567A (en) | Virus nucleic acid mutation detection method and application | |
Luo et al. | Two-point-one-line modularized strategy combined with Holliday-junction button probes for multiloci SNPs long-range distribution analysis | |
McTaggart et al. | Selection on the structural stability of a ribosomal RNA expansion segment in Daphnia obtusa | |
Gerczei et al. | Biochemistry laboratory manual for undergraduates: an inquiry-based approach | |
EP4289972A1 (en) | Method for detecting methicillin resistant staphylococcus aureus | |
Rubin et al. | Strong, specific binding of six different DNA sequences by a single conformation-switching DNA macrocycle | |
WO1997011199A9 (en) | Nucleic acid reactions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
COP | Corrected version of pamphlet |
Free format text: PAGES 7/11 AND 8/11,DRAWINGS,REPLACED BY NEW PAGES BEARING THE SAME NUMBER |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2165163 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994920751 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1994920751 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994920751 Country of ref document: EP |